4D Molecular Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

4D Molecular Therapeutics

10/05/2023 22:09

* 4D Molecular Therapeutics Inc  FDMT.OQ  reported a
quarterly
adjusted loss of 88 cents​​ per share for the quarter ended in
March. The mean expectation of five analysts for the quarter was
for a loss of 90 cents per share.
    * Revenue fell 75.6% to $298.00 thousand from a year ago;
analysts
expected $1.03 million. 
    * 4D Molecular Therapeutics Inc's reported EPS for the
quarter was
a loss of 88 cents​.
    * The mean earnings estimate of analysts had risen by
about 1.5%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * 4D Molecular Therapeutics Inc shares had risen by 0.8%
this
quarter and lost 22.0% so far this year.
    * The company reported a quarterly loss of $28.68 million.
    * Wall Street's median 12-month price target for 4D
Molecular
Therapeutics Inc is $36.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
10 at 09:09 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.90          -0.88          Beat
 Dec. 31 2022      -0.79          -0.84          Missed
 Sep. 30 2022      -0.91          -0.79          Beat
 Jun. 30 2022      -0.85          -0.87          Missed